MTNB has far more activity on Stock Twits.
I agree that good things are ahead for MTNB with the results of two Phase II clinical trials for encochleated amphotericin B to be announced in June. If the results are good, as I expect they will be, the company will likely be on the radar of a number of big pharma companies either to license MTNB's patented encochleation process for their own toxic but effective drugs, or to invest in or buy out Matinas while it still has a low market cap.
Exciting times are ahead for Matinas.
News 
Market Data 
Discover 
